Key result
An improved synthesis was developed for rivaroxaban, an oral, selective direct factor Xa inhibitor approved for the prevention of venous thromboembolism.
Describes an improved chemical synthesis of the factor Xa inhibitor rivaroxaban.
Answers are grounded in this paper and cite their sources.
No immediate change to rivaroxaban use; extends laboratory routes for factor Xa inhibitor synthesis.
Rivaroxaban (1) is a novel, oral, selective direct inhibitor of factor Xa developed by Bayer Healthcare.1,2 It has been approved by the EMEA and FDA for the prevention of venous thromboembolism in ...
No takes yet. Share an insight, caveat, or question.
Tian et al. (2017) studied this question. An improved synthesis was developed for rivaroxaban, an oral, selective direct factor Xa inhibitor approved for the prevention of venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: